<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39550517</article-id><article-id pub-id-type="pmc">PMC11785652</article-id>
<article-id pub-id-type="publisher-id">7533</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07533-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Effects on lymph node size, staging and primary tumor histology on diagnostic accuracy of axillary lymph node aspirate of breast cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Joshua J. X.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Joanna K. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hon</surname><given-names>Nikki K. Y.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>See</surname><given-names>Ka Wun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tsang</surname><given-names>Julia Y. S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tse</surname><given-names>Gary M.</given-names></name><address><email>garytse@cuhk.edu.hk</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000000121742757</institution-id><institution>Department of Pathology, School of Clinical Medicine, Queen Mary Hospital, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong Island, Hong Kong </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t33hh48</institution-id><institution-id institution-id-type="GRID">grid.10784.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0482</institution-id><institution>Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, </institution><institution>The Chinese University of Hong Kong, </institution></institution-wrap>1/F, Clinical Sciences Building, New Territories, Hong Kong </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01g171x08</institution-id><institution-id institution-id-type="GRID">grid.413608.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 5868</institution-id><institution>Department of Pathology, </institution><institution>Alice Ho Miu Ling Nethersole Hospital, </institution></institution-wrap>New Territories, Hong Kong </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rh36007</institution-id><institution-id institution-id-type="GRID">grid.490321.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 2990</institution-id><institution>Department of Pathology, </institution><institution>North District Hospital, </institution></institution-wrap>New Territories, Hong Kong </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><history><date date-type="received"><day>15</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Fine-needle aspiration cytology is preferred for axillary lymph node metastasis with low costs and minimal risks. To improve diagnostic performance by incorporating clinical-radiological-pathological parameters, a large cohort pre-operative aspirates in were reviewed for parameters affecting adequacy rate and accuracy.</p></sec><sec><title>Methods</title><p id="Par2">Axillary nodal aspirates from three institutions with histologic correlation were retrieved. Case notes were reviewed for parameters pertaining to the primary tumor, nodal status, histologic and cytologic diagnoses.</p></sec><sec><title>Results</title><p id="Par3">Totally 1361 specimens were included. The risk of malignancy for C1&#x02013;C5 categories were 53.39%, 27.45%, 70.97%, 83.33% and 88.00%, increasing to 75.86%, 94.59% and 99.28% for C3/C4/C5 categories excluding cases with neoadjuvant therapy. Node size (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and histologic grade (<italic>p</italic>&#x02009;=&#x02009;0.003) of primary tumor positively correlated with specimen adequacy. Presence of in situ component trended towards inadequacy (<italic>p</italic>&#x02009;=&#x02009;0.069). Lymph node size remained a strong predictor of concordant cytologic diagnosis (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). A higher percentage of involved node (<italic>p</italic>&#x02009;=&#x02009;0.006) and HER2 overexpressed breast cancers (<italic>p</italic>&#x02009;=&#x02009;0.027) increased concordance. Cases with&#x02009;&#x02265;&#x02009;4 (up to&#x02009;&#x02265;&#x02009;10) positive nodes were more likely to be concordant (<italic>p</italic>&#x02009;=&#x02009;0.009&#x02013;&#x02009;&#x0003c;&#x02009;0.001), with improvements of 8.27%&#x02013;12.37%. For size, cut-offs of&#x02009;&#x02265;&#x02009;5 and&#x02009;&#x02265;&#x02009;10&#x000a0;mm were significant (<italic>p</italic>&#x02009;=&#x02009;0.006&#x02013;&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec><title>Conclusion</title><p id="Par4">It is critical that clinical-radiological-pathological findings be interpreted together with cytology. Aspirates from smaller nodes are more likely to be non-informative, irrespective of the total number of suspicious nodes, or a high-grade primary. In axillae with less than 4 suspicious nodes and/or a target node of less than 5&#x02013;10&#x000a0;mm, the diagnostic accuracy of aspiration cytology decreases and should be interpreted cautiously.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast</kwd><kwd>Cytology</kwd><kwd>Fine-needle aspiration</kwd><kwd>Lymph node</kwd><kwd>Metastasis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">In the assessment of axillary lymph node status for breast cancers, fine-needle aspiration cytology is the preferred diagnostic modality with a low cost and minimal risk of complications [<xref ref-type="bibr" rid="CR1">1</xref>]. Although it has been widely accepted that lymph node aspiration cytology, for detection of metastasis, is highly specific with slight limitations on sensitivity [<xref ref-type="bibr" rid="CR2">2</xref>], the application of aspiration cytology for breast cancer metastasis is different. Clinical, radiological and histopathological findings of the lymph node and primary tumor are usually available before aspiration is performed, unlike in the assessment of lymphadenopathies of unknown nature [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In this study, a large cohort of axillary lymph node aspirates in pre-operative assessment for breast cancer patients were reviewed for lymph node and histopathological parameters affecting the adequacy rate and accuracy of cytologic diagnosis.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par6">Computerized searches of the three involved institutions for axillary node fine-needle aspirate cytology specimens were performed (Alice Ho Miu Ling Nethersole Hospital and North District Hospital: from the year 2000 to 2022; Prince of Wales Hospital from the year 1997 to 2022). Cytologic diagnoses were reclassified into a five-tiered system&#x02014;inadequate/unsatisfactory (C1), benign (C2), atypia (C3), suspicious for malignancy (C4) and malignant (C5). Case notes and pathology reports of each patient was reviewed, and those with corresponding sentinel lymph node core or excision biopsy and/or axillary lymph node dissection performed were included (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Radiology reports, pathology reports and clinical notes were reviewed in sequence for the greatest diameter of the target lymph node (i.e., clinical dimensions taken when radiological and pathological sizing were not present). Histological parameters of the primary breast tumor, including histological type, histological grade and presence of in situ components were recorded from corresponding breast biopsy and/or surgical excision reports. Case notes, cytology reports and/or slides with a false positive result (no histologic evidence of lymph node metastasis but a cytologic diagnosis of C3, C4 or C5) were further reviewed for possible causes including but not limited to interval neoadjuvant treatment, other neoplasms involving the axilla and cytologic interpretation.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Axillary lymph node aspirate and corresponding histology, <bold>a</bold> scattered irregular atypical cells, the cytologic diagnosis was C3 (atypia), 400&#x02009;&#x000d7;&#x02009;magnification, <bold>b</bold> Axillary dissection showed metastatic lobular carcinoma, 100&#x02009;&#x000d7;&#x02009;magnification</p></caption><graphic xlink:href="10549_2024_7533_Fig1_HTML" id="MO1"/></fig></p><p id="Par7">Statistical analysis was performed using SPSS (version 26.0). The chi-squared test and t-test were used to compare lymph node parameters including the size of the targeted lymph node, number of positive and total number of lymph nodes excised, and histological parameters of the primary tumor. Comparisons were made between inadequate (C1) and adequate (C2-C5) specimens, and between concordant and discordant cases at binary cutoffs considering atypia or higher-grade cytologic diagnoses (C3&#x02009;+) or suspicious or higher-grade cytologic diagnoses (C4&#x02009;+) as positive and excluding C1 specimens. A <italic>p</italic>-value of&#x02009;&#x0003c;&#x02009;0.05 was considered as significant. The study was approved by The Joint Chinese University of Hong Kong &#x02013; New Territories East Cluster Clinical Research Ethics Committee. <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographics of the cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Total number of cases</th><th align="left">1361</th></tr></thead><tbody><tr><td align="left" colspan="2">Laterality</td></tr><tr><td align="left">&#x000a0;Left</td><td align="left">697</td></tr><tr><td align="left">&#x000a0;Right</td><td align="left">664</td></tr><tr><td align="left" colspan="2">Histologic type</td></tr><tr><td align="left">&#x000a0;Apocrine carcinoma</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Ductal carcinoma in situ</td><td align="left">68</td></tr><tr><td align="left">&#x000a0;Invasive ductal carcinoma</td><td align="left">1094</td></tr><tr><td align="left">&#x000a0;Invasive lobular carcinoma</td><td align="left">43</td></tr><tr><td align="left">&#x000a0;Lobular carcinoma in situ</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Mucinous carcinoma</td><td align="left">27</td></tr><tr><td align="left">&#x000a0;Medullary carcinoma</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;Metaplastic carcinoma</td><td align="left">13</td></tr><tr><td align="left">&#x000a0;Mixed</td><td align="left">27</td></tr><tr><td align="left">&#x000a0;Neuroendocrine carcinoma</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Papillary carcinoma</td><td align="left">14</td></tr><tr><td align="left">&#x000a0;Phyllodes tumor</td><td align="left">2</td></tr><tr><td align="left">&#x000a0;Sarcoma</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Tubular carcinoma</td><td align="left">2</td></tr><tr><td align="left">&#x000a0;Invasive carcinoma/malignancy, not-specified</td><td align="left">64</td></tr><tr><td align="left" colspan="2">Histological grade</td></tr><tr><td align="left">&#x000a0;Grade 1</td><td align="left">166</td></tr><tr><td align="left">&#x000a0;Grade 2</td><td align="left">550</td></tr><tr><td align="left">&#x000a0;Grade 3</td><td align="left">463</td></tr><tr><td align="left" colspan="2">Surrogate molecular subtype</td></tr><tr><td align="left">&#x000a0;Luminal (A/B)</td><td align="left">164</td></tr><tr><td align="left">&#x000a0;HER2 overexpressed</td><td align="left">868</td></tr><tr><td align="left">&#x000a0;Triple negative</td><td align="left">198</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec3"><title>Results</title><p id="Par8">A total of 1361 fine-needle aspiration cytology specimens were included, with 697 from the left and 664 from the right axilla. The primary breast tumor was invasive ductal carcinoma (invasive breast carcinoma, no special type) (<italic>n</italic>&#x02009;=&#x02009;1094/1361 80.38%), followed by ductal carcinoma in situ (<italic>n</italic>&#x02009;=&#x02009;68/1361, 5.00%) and invasive lobular carcinoma (<italic>n</italic>&#x02009;=&#x02009;43/1361, 3.16%)&#x000a0;(Table <xref rid="Tab1" ref-type="table">1</xref>). The risk of malignancy for the C1 to C5 categories were 53.39%, 27.45%, 70.97%, 83.33% and 88.00%, increasing to 75.86%, 94.59% and 99.28% for the C3, C4 and C5 categories when cases with neoadjuvant therapy were excluded (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Risk of malignancy (ROM) in each cytologic category</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total ROM</th><th align="left">ROM excluding cases with neoadjuvant therapy</th></tr></thead><tbody><tr><td align="left">C1</td><td align="left">53.39% (71/133)</td><td align="left"/></tr><tr><td align="left">C2</td><td align="left">27.45% (137/499)</td><td align="left"/></tr><tr><td align="left">C3</td><td align="left">70.97% (44/62)</td><td align="left">75.86% (44/58)</td></tr><tr><td align="left">C4</td><td align="left">83.33% (35/42)</td><td align="left">94.59% (35/37)</td></tr><tr><td align="left">C5</td><td align="left">88.00% (550/625)</td><td align="left">99.28% (550/554)</td></tr></tbody></table></table-wrap></p><p id="Par9">Comparison of inadequate and adequate specimens demonstrated that the greatest diameter of the target lymph node (i.e., size) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and the histologic grade (<italic>p</italic>&#x02009;=&#x02009;0.003) of the primary tumor were positively correlated with an adequate cytologic diagnosis. The presence of an in situ component in the primary breast tumor showed a trend towards an inadequate cytologic diagnosis (<italic>p</italic>&#x02009;=&#x02009;0.069). The number of positive lymph nodes, total number of lymph nodes, percentage of positive nodes and surrogate molecular subtype did not correlate with specimen adequacy (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Correlation between lymph node and primary tumor parameters with specimen adequacy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Inadequate (C1)</th><th align="left">Adequate (C2-C5)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">No. of positive lymph nodes</td><td align="left">2.58</td><td align="left">3.25</td><td char="." align="char">0.339</td></tr><tr><td align="left">Total no. of lymph nodes</td><td align="left">14.25</td><td align="left">15.22</td><td char="." align="char">0.146</td></tr><tr><td align="left">% of positive lymph nodes</td><td align="left">18.19%</td><td align="left">20.57%</td><td char="." align="char">0.197</td></tr><tr><td align="left">Greatest diameter (mm)</td><td align="left">9.05</td><td align="left">13.15</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="4">Histologic grade</td></tr><tr><td align="left">&#x000a0;Grade I</td><td align="left">29</td><td align="left">137</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grade II</td><td align="left">48</td><td align="left">502</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grade III</td><td align="left">42</td><td align="left">421</td><td char="." align="char">0.003</td></tr><tr><td align="left" colspan="4">In situ component</td></tr><tr><td align="left">&#x000a0;Present</td><td align="left">91</td><td align="left">741</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Absent</td><td align="left">42</td><td align="left">487</td><td char="." align="char">0.069</td></tr><tr><td align="left" colspan="4">Surrogate molecular subtype</td></tr><tr><td align="left">&#x000a0;Luminal</td><td align="left">16</td><td align="left">148</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;HER2 overexpressed</td><td align="left">88</td><td align="left">780</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Triple negative</td><td align="left">13</td><td align="left">185</td><td char="." align="char">0.301</td></tr></tbody></table></table-wrap></p><p id="Par10">The greatest diameter of the target lymph node remained a strong predictor of concordance in two cytologic diagnosis categorical cut-offs, with a p-value of less than 0.001. A higher percentage of involved lymph node (<italic>p</italic>&#x02009;=&#x02009;0.006) and HER2 overexpressed breast cancers (<italic>p</italic>&#x02009;=&#x02009;0.027) were associated greater concordance rates, considering C4 and C5 as a positive diagnostic result. Other parameters compared did not show statistical significance, and except for lymph node diameter, no other parameter was significantly correlated with concordance when cytologic diagnoses of C3 or above were taken as positive (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Comparison of diagnostic concordance with lymph node and primary tumor parameters a) considering C3 (atypia) or b) C4 (suspicious) or above as positive</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">(a) Concordant</th><th align="left">Discordant</th><th align="left"><italic>p</italic>-value</th><th align="left">(b) Concordant</th><th align="left">Discordant</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">No. of positive lymph nodes</td><td align="left">3.68</td><td align="left">2.20</td><td char="." align="char">0.346</td><td align="left">3.57</td><td align="left">3.03</td><td char="." align="char">0.083</td></tr><tr><td align="left">Total no. of lymph nodes</td><td align="left">15.32</td><td align="left">14.07</td><td char="." align="char">0.080</td><td align="left">15.17</td><td align="left">15.06</td><td char="." align="char">0.870</td></tr><tr><td align="left">% of positive lymph nodes</td><td align="left">21.70%</td><td align="left">23.95%</td><td char="." align="char">0.346</td><td align="left">21.03%</td><td align="left">27.10%</td><td char="." align="char">0.006</td></tr><tr><td align="left">Greatest diameter (mm)</td><td align="left">13.20</td><td align="left">10.02</td><td char="." align="char">0.001</td><td align="left">13.25</td><td align="left">10.46</td><td char="." align="char">0.001</td></tr><tr><td align="left" colspan="7">Histologic grade</td></tr><tr><td align="left">&#x000a0;Grade I</td><td align="left">104</td><td align="left">24</td><td char="." align="char"/><td align="left">102</td><td align="left">26</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grade II</td><td align="left">410</td><td align="left">69</td><td char="." align="char"/><td align="left">400</td><td align="left">79</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grade III</td><td align="left">357</td><td align="left">46</td><td char="." align="char">0.094</td><td align="left">344</td><td align="left">59</td><td char="." align="char">0.310</td></tr><tr><td align="left" colspan="7">In situ component</td></tr><tr><td align="left">&#x000a0;Present</td><td align="left">600</td><td align="left">100</td><td char="." align="char"/><td align="left">579</td><td align="left">121</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Absent</td><td align="left">391</td><td align="left">57</td><td char="." align="char">0.452</td><td align="left">384</td><td align="left">64</td><td char="." align="char">0.177</td></tr><tr><td align="left" colspan="7">Surrogate molecular subtype</td></tr><tr><td align="left">&#x000a0;Luminal (A/B)</td><td align="left">118</td><td align="left">14</td><td char="." align="char"/><td align="left">117</td><td align="left">15</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;HER2 overexpressed</td><td align="left">630</td><td align="left">115</td><td char="." align="char"/><td align="left">606</td><td align="left">139</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Triple negative</td><td align="left">153</td><td align="left">19</td><td char="." align="char">0.153</td><td align="left">151</td><td align="left">21</td><td char="." align="char">0.027</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Cases with neoadjuvant treatment excluded</p></table-wrap-foot></table-wrap></p><p id="Par11">The concordance rates for cases with at least one positive lymph node compared to all lymph nodes negative were lower (C3&#x02009;+&#x02009;: 82.11% vs. 94.76%; C4&#x02009;+&#x02009;: 76.63% vs. 98.43%). However, the difference in concordance rates were reversed at higher cut-offs. Aspirates in cases with at least 4 or more (and at least 10 or more) positive lymph nodes were more likely to be concordant (<italic>p</italic>&#x02009;=&#x02009;0.009&#x02013;&#x0003c;&#x02009;0.001), with differences in concordance rates at 8.27% to 12.37%. As for the greatest diameter of the target lymph node, a greater diameter was associated with higher concordance rates consistently, with significant differences at cut-offs of&#x02009;&#x02265;&#x02009;5&#x000a0;mm (<italic>p</italic>&#x02009;=&#x02009;0.001 and <italic>p</italic>&#x02009;=&#x02009;0.006) and&#x02009;&#x02265;&#x02009;10&#x000a0;mm (p&#x02009;&#x0003c;&#x02009;0.001) and statistical trends at&#x02009;&#x02265;&#x02009;20&#x000a0;mm (<italic>p</italic>&#x02009;=&#x02009;0.090 and <italic>p</italic>&#x02009;=&#x02009;0.051) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Diagnostic concordance according to lymph node parameters (a) considering C3 (atypia) or (b) C4 (suspicious) or above as positive at different cut-offs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">(a) Concordant</th><th align="left">Discordant</th><th align="left">Concordance rate</th><th align="left"><italic>p</italic>-value</th><th align="left">(b) Concordant</th><th align="left">Discordant</th><th align="left"><italic>p</italic>-value</th><th align="left">Concordance rate</th></tr></thead><tbody><tr><td align="left">No. of positive nodes</td><td align="left"/><td align="left"/><td align="left">(Yes/no)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left">(Yes/No)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;10 (Yes/no)</td><td align="left">114/877</td><td align="left">3/154</td><td align="left">97.44%/85.06%</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">108/855</td><td align="left">9/176</td><td char="." align="char">0.009</td><td align="left">92.31%/82.93%</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;4 (Yes/no)</td><td align="left">333/658</td><td align="left">29/128</td><td align="left">91.99%/83.72%</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">314/649</td><td align="left">48/137</td><td char="." align="char">0.074</td><td align="left">86.74%/82.57%</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;3 (Yes/no)</td><td align="left">401/590</td><td align="left">51/106</td><td align="left">88.72%/84.77%</td><td align="left">0.057</td><td align="left">378/585</td><td align="left">74/111</td><td char="." align="char">0.849</td><td align="left">83.63%/84.05%</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;2 (Yes/no)</td><td align="left">500/491</td><td align="left">81/76</td><td align="left">86.06%/86.60%</td><td align="left">0.791</td><td align="left">466/497</td><td align="left">115/70</td><td char="." align="char">0.001</td><td align="left">80.21%/87.65%</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;1 (Yes/no)</td><td align="left">629/362</td><td align="left">137/20</td><td align="left">82.11%/94.76%</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">587/376</td><td align="left">179/6</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">76.63%/98.43%</td></tr><tr><td align="left">Greatest diameter</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x02265;&#x02009;20&#x000a0;mm (Yes/no)</td><td align="left">122/537</td><td align="left">11/85</td><td align="left">91.73%/86.33%</td><td align="left">0.090</td><td align="left">119/514</td><td align="left">14/108</td><td char="." align="char">0.051</td><td align="left">89.47%/82.64%</td></tr><tr><td align="left">&#x000a0;&#x02009;&#x02265;&#x02009;10&#x000a0;mm (Yes/no)</td><td align="left">415/244</td><td align="left">40/56</td><td align="left">91.21%/81.33%</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">398/235</td><td align="left">57/65</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">87.47%/78.33%</td></tr><tr><td align="left">&#x000a0;&#x02009;&#x02265;&#x02009;5&#x000a0;mm (Yes/no)</td><td align="left">576/83</td><td align="left">72/24</td><td align="left">88.89%/77.57%</td><td align="left">0.001</td><td align="left">553/80</td><td align="left">95/27</td><td char="." align="char">0.006</td><td align="left">85.34%/74.77%</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Cases with neoadjuvant treatment excluded</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Discussion</title><p id="Par12">Axillary lymph node metastasis is a strong prognostic indicator in breast cancer [<xref ref-type="bibr" rid="CR5">5</xref>]. The treatment options are axillary lymph node dissection, radiotherapy and/or combinations with other systemic therapy [<xref ref-type="bibr" rid="CR6">6</xref>]. Axillary recurrence is associated with significant morbidity and mortality [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], with nearly half of the patients further developing distant metastases [<xref ref-type="bibr" rid="CR9">9</xref>]. On the other hand, axillary dissection and regional radiotherapy are associated with risks of functional morbidities such as lymphedema, paresthesia and other forms of impairment [<xref ref-type="bibr" rid="CR10">10</xref>]. Both overtreatment and undertreatment should be avoided. Accurate pre-operative diagnosis is necessary in preventing inadequate treatment.</p><p id="Par13">The triple assessment also applies to the axilla [<xref ref-type="bibr" rid="CR11">11</xref>]. Fine-needle aspiration is highly suited for breast and axillary lymph node biopsy [<xref ref-type="bibr" rid="CR12">12</xref>]. With the superficial and palpable location of the axillary nodes, the need of puncture in multiple directions to adequately sample a lymph node, and a relatively favorable cost and complication profile of fine-needle aspiration over core biopsy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], axillary lymph node aspiration is often used in primary tissue diagnosis for axillary nodal status. Despite extensive literature highlighting the specificity of axillary lymph node aspiration cytology [<xref ref-type="bibr" rid="CR14">14</xref>], two caveats must be addressed &#x02013; the diagnostic accuracy of cytology depends on how the diagnostic categories are attributed (in particular the atypia group) [<xref ref-type="bibr" rid="CR2">2</xref>], and cytology results are not interpreted in isolation but with clinical and radiological findings. In this study, the histologic correlation of axillary lymph node aspiration from a cohort including multiple centers and collected through an extended period, were reviewed in correlation with clinical and radiological parameters to detail the diagnostic performance and possible effects of clinical and radiological features.</p><p id="Par14">In line with the literature, the sensitivity of axillary lymph node aspiration cytology was modest, with a 27.45% ROM, equivalent to the false negative rate [<xref ref-type="bibr" rid="CR14">14</xref>]. The ROMs of the C3 to C5 categories were initially slightly low, ranging from 70% to less than 90%, but when cases with neoadjuvant therapy were excluded, the ROMs of C4 and C5 categories improved to 94.50% and 99.28%. There were 16, 2, and 4 false positives in the C3, C4 and C5 categories, respectively. Review of the cases found one with primary sarcoma involving the axillary region, and one case with ductal carcinoma in situ involving the axillary tail, without invasion nor lymph node involvement. The remaining 18 were all attributed to interpretative errors (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par15">Inadequate aspiration necessitates repeat biopsy and leads to delay in management and increased resources consumption [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. It should be noted that the risk of malignancy for inadequate specimens is significantly higher than C2 and cannot be considered as a &#x0201c;provisionally&#x0201d; benign diagnosis. There were also 68 cases of ductal carcinoma in situ included for analysis, of which 10 had histologic evidence of lymph node metastasis. Ductal carcinoma in situ with metastasis is a well reported phenomenon that is largely attributed to sampling error and minute undetected or undetectable invasive foci [<xref ref-type="bibr" rid="CR17">17</xref>], as such the cases were included for analysis. Two inadequate diagnosis that had positive lymph node histology were also present in the group of ductal carcinoma in situ, indicating that even in low-risk cases, inadequate aspirates necessitate further workup.</p><p id="Par16">Excisional or sentinel node biopsy may be preferable when pre-operative diagnostic yield is expected to be low, such as in cases of classical lobular carcinoma (<xref ref-type="bibr" rid="CR18">18</xref>). Low-grade histology and small lymph node size were associated with an increased inadequacy rate in the current cohort. Omission of substitution of fine-needle aspiration by other biopsy modalities such be considered for these cases. Of note, only the size of the target, node demonstrated correlation, whereas the total number of positive nodes does not affect adequacy rate, suggesting that targeting the largest node is necessary even when there are multiple suspicious lymph nodes.</p><p id="Par17">The limitations of the study includes the heterogeneity of cases over a long collection period, with different clinical guidelines and protocols adopted, and its retrospective design. Clinically and radiologically low-risk cases, particularly those with benign or inadequate aspirates, may not be subjected to further axillary lymph node dissection or even core or excisional biopsy. On the other hand, patients with advanced disease also may not be treated surgically and thus not captured in the cohort. The requirement of histological correlation skewed the composition of breast cancer cases and would not match the composition histological or molecular typing in the breast cancers of the general population.</p><p id="Par18">As for clinical and radiological parameters affecting the diagnostic performance of lymph node aspiration, lymph node size was identified as a consistent predictor of concordance regardless of cut-off adopted in cytologic diagnostic category. Cases with higher percentage of involved lymph node and HER2 overexpressed breast cancers showed higher concordance at the C4 or above cut-off but not for C3 or above. Further analysis pertaining to these significant parameters showed that for size, lymph nodes with greatest dimension of greater or equal to 5&#x000a0;mm and 10&#x000a0;mm statistically significantly improved diagnostic accuracy, and a trend was observed for the cut-off at least 20&#x000a0;mm. The concordance rate also increased with the number of positive nodes, reaching statistical significance at the threshold of greater or equal to 4 positive nodes. These figures can serve as a reference in deciding whether fine-needle aspiration should be proceeded, or in cases where there is discrepancy between cytologic diagnosis, clinical impression and radiological findings, further investigation is needed for clarification.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par19">Fine-needle aspiration is specific but suffers from a lower sensitivity in detecting lymph node metastasis. As such, it is critical that clinical and radiological findings be examined together with cytologic results. Smaller lymph nodes are more likely to be non-informative on aspiration cytology, irrespective of whether other suspicious lymph nodes are present, or if the primary lesion if of a high histologic grade. In axillae with less than 4 suspicious lymph nodes and/or a target lymph node of less than 5&#x02013;10&#x000a0;mm, the diagnostic accuracy of axillary lymph node aspiration decreases and should be interpreted with caution.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>JJXL&#x02014;conceptualization, formal analysis, investigation, methodology, visualization, writing&#x02014;original draft; JKMN&#x02014;formal analysis, methodology, investigation; NKYH&#x02014;investigation; KWS&#x02014;investigation; JYT&#x02014;validation, writing&#x02014;review and editing; GMT&#x02014;conceptualization, methodology, resources, supervision, writing&#x02014;review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors have no funding to declare.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The authors declare all data generated are available in the manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par20">The authors declare that there is no conflict of interest regarding the publication of this paper.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par21">The study was approved by the Joint Chinese University of Hong Kong &#x02013; New Territories East Cluster Clinical Research Ethics Committee with waiver of written consent (reference number 2022.061).</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Marabi</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>JJX</given-names></name><name><surname>Chan</surname><given-names>WK</given-names></name><name><surname>Tsang</surname><given-names>JY</given-names></name><name><surname>Tse</surname><given-names>GM</given-names></name></person-group><article-title>Axillary nodal metastasis with papillary morphology: an uncommon origin</article-title><source>Acta Cytol</source><year>2020</year><volume>64</volume><issue>6</issue><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1159/000508241</pub-id><pub-id pub-id-type="pmid">32526747</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Marabi M, Li JJX, Chan WK, Tsang JY, Tse GM (2020) Axillary nodal metastasis with papillary morphology: an uncommon origin. Acta Cytol 64(6):612&#x02013;616<pub-id pub-id-type="pmid">32526747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>SN</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SI</given-names></name><name><surname>Tsang</surname><given-names>JYS</given-names></name><name><surname>Ni</surname><given-names>YB</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Atypical aspirates of the breast: a dilemma in current cytology practice</article-title><source>J Clin Pathol</source><year>2017</year><volume>70</volume><issue>12</issue><fpage>1024</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2016-204138</pub-id><pub-id pub-id-type="pmid">28554890</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Yu SN, Li J, Wong SI, Tsang JYS, Ni YB, Chen J et al (2017) Atypical aspirates of the breast: a dilemma in current cytology practice. J Clin Pathol 70(12):1024&#x02013;1032<pub-id pub-id-type="pmid">28554890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>RCK</given-names></name><name><surname>Lee</surname><given-names>ALS</given-names></name><name><surname>To</surname><given-names>CCK</given-names></name><name><surname>Cheung</surname><given-names>TLH</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Choi</surname><given-names>JSH</given-names></name><etal/></person-group><article-title>The role of cytokeratin 7/20 coordination revisited&#x02014;machine learning identifies improved interpretative algorithms for cell block immunohistochemistry in aspirates of metastatic carcinoma</article-title><source>Cancer Cytopathol</source><year>2022</year><volume>130</volume><issue>6</issue><fpage>455</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1002/cncy.22559</pub-id><pub-id pub-id-type="pmid">35213075</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chan RCK, Lee ALS, To CCK, Cheung TLH, Ho CT, Choi JSH et al (2022) The role of cytokeratin 7/20 coordination revisited&#x02014;machine learning identifies improved interpretative algorithms for cell block immunohistochemistry in aspirates of metastatic carcinoma. Cancer Cytopathol 130(6):455&#x02013;468<pub-id pub-id-type="pmid">35213075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJX</given-names></name><name><surname>Ng</surname><given-names>JKM</given-names></name><name><surname>Aphivatanasiri</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>RCK</given-names></name><name><surname>Poon</surname><given-names>IK</given-names></name><name><surname>Tsang</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Fine needle aspiration cytology of metastatic carcinomas with papillary architecture: a systemic assessment of clinical, cytological and immunohistochemical parameters</article-title><source>Cytopathology</source><year>2022</year><volume>33</volume><issue>3</issue><fpage>328</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/cyt.13110</pub-id><pub-id pub-id-type="pmid">35147260</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Li JJX, Ng JKM, Aphivatanasiri C, Chan RCK, Poon IK, Tsang JY et al (2022) Fine needle aspiration cytology of metastatic carcinomas with papillary architecture: a systemic assessment of clinical, cytological and immunohistochemical parameters. Cytopathology 33(3):328&#x02013;343<pub-id pub-id-type="pmid">35147260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>BS</given-names></name><name><surname>Tsang</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Poon</surname><given-names>IK</given-names></name><name><surname>Tse</surname><given-names>GM</given-names></name></person-group><article-title>Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival</article-title><source>Histopathology</source><year>2023</year><volume>82</volume><issue>6</issue><fpage>899</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1111/his.14875</pub-id><pub-id pub-id-type="pmid">36723261</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lai BS, Tsang JY, Li JJ, Poon IK, Tse GM (2023) Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival. Histopathology 82(6):899&#x02013;911<pub-id pub-id-type="pmid">36723261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Spruit</surname><given-names>PH</given-names></name><name><surname>Siesling</surname><given-names>S</given-names></name><name><surname>Elferink</surname><given-names>MA</given-names></name><name><surname>Vonk</surname><given-names>EJ</given-names></name><name><surname>Hoekstra</surname><given-names>CJ</given-names></name></person-group><article-title>Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up</article-title><source>Radiat Oncol</source><year>2007</year><pub-id pub-id-type="doi">10.1186/1748-717X-2-40</pub-id><pub-id pub-id-type="pmid">17971196</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Spruit PH, Siesling S, Elferink MA, Vonk EJ, Hoekstra CJ (2007) Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol. 10.1186/1748-717X-2-40<pub-id pub-id-type="pmid">17971196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Voogd</surname><given-names>AC</given-names></name><name><surname>Cranenbroek</surname><given-names>S</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><name><surname>Roumen</surname><given-names>RMH</given-names></name><name><surname>Rutten</surname><given-names>HJT</given-names></name><name><surname>van der Sangen</surname><given-names>MJC</given-names></name></person-group><article-title>Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer</article-title><source>Eur J Surg Oncol (EJSO)</source><year>2005</year><volume>31</volume><issue>5</issue><fpage>485</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2004.12.017</pub-id><pub-id pub-id-type="pmid">15922883</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Voogd AC, Cranenbroek S, de Boer R, Roumen RMH, Rutten HJT, van der Sangen MJC (2005) Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer. Eur J Surg Oncol (EJSO) 31(5):485&#x02013;489<pub-id pub-id-type="pmid">15922883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Moore MP, Kinne DW. (1996) Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Important Adv Oncol. 245&#x02013;50.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Konkin</surname><given-names>DE</given-names></name><name><surname>Tyldesley</surname><given-names>S</given-names></name><name><surname>Kennecke</surname><given-names>H</given-names></name><name><surname>Speers</surname><given-names>CH</given-names></name><name><surname>Olivotto</surname><given-names>IA</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name></person-group><article-title>Management and outcomes of isolated axillary node recurrence in breast cancer</article-title><source>Arch Surg</source><year>2006</year><volume>141</volume><issue>9</issue><fpage>867</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1001/archsurg.141.9.867</pub-id><pub-id pub-id-type="pmid">16983030</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Konkin DE, Tyldesley S, Kennecke H, Speers CH, Olivotto IA, Davis N (2006) Management and outcomes of isolated axillary node recurrence in breast cancer. Arch Surg 141(9):867&#x02013;874<pub-id pub-id-type="pmid">16983030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Abass</surname><given-names>MO</given-names></name><name><surname>Gismalla</surname><given-names>MDA</given-names></name><name><surname>Alsheikh</surname><given-names>AA</given-names></name><name><surname>Elhassan</surname><given-names>MMA</given-names></name></person-group><article-title>Axillary lymph node dissection for breast cancer: efficacy and complication in developing countries</article-title><source>J Global Oncol</source><year>2018</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Abass MO, Gismalla MDA, Alsheikh AA, Elhassan MMA (2018) Axillary lymph node dissection for breast cancer: efficacy and complication in developing countries. J Global Oncol 4:1&#x02013;8</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JM</given-names></name><name><surname>Leung</surname><given-names>JWT</given-names></name><name><surname>Moy</surname><given-names>L</given-names></name><name><surname>Ha</surname><given-names>SM</given-names></name><name><surname>Moon</surname><given-names>WK</given-names></name></person-group><article-title>Axillary nodal evaluation in breast cancer: state of the art</article-title><source>Radiology</source><year>2020</year><volume>295</volume><issue>3</issue><fpage>500</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020192534</pub-id><pub-id pub-id-type="pmid">32315268</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chang JM, Leung JWT, Moy L, Ha SM, Moon WK (2020) Axillary nodal evaluation in breast cancer: state of the art. Radiology 295(3):500&#x02013;515<pub-id pub-id-type="pmid">32315268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Jamidi</surname><given-names>SK</given-names></name><name><surname>Li</surname><given-names>JJX</given-names></name><name><surname>Aphivatanasiri</surname><given-names>C</given-names></name><name><surname>Chow</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>RCK</given-names></name><name><surname>Ng</surname><given-names>JKM</given-names></name><etal/></person-group><article-title>Papillary lesions of the breast: a systematic evaluation of cytologic parameters</article-title><source>Cancer Cytopathol</source><year>2021</year><volume>129</volume><issue>8</issue><fpage>649</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1002/cncy.22412</pub-id><pub-id pub-id-type="pmid">33561323</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Jamidi SK, Li JJX, Aphivatanasiri C, Chow M, Chan RCK, Ng JKM et al (2021) Papillary lesions of the breast: a systematic evaluation of cytologic parameters. Cancer Cytopathol 129(8):649&#x02013;661<pub-id pub-id-type="pmid">33561323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Mainiero</surname><given-names>MB</given-names></name><name><surname>Cinelli</surname><given-names>CM</given-names></name><name><surname>Koelliker</surname><given-names>SL</given-names></name><name><surname>Graves</surname><given-names>TA</given-names></name><name><surname>Chung</surname><given-names>MA</given-names></name></person-group><article-title>Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance</article-title><source>Am J Roentgenol</source><year>2010</year><volume>195</volume><issue>5</issue><fpage>1261</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.2214/AJR.10.4414</pub-id><pub-id pub-id-type="pmid">20966338</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA (2010) Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. Am J Roentgenol 195(5):1261&#x02013;1267<pub-id pub-id-type="pmid">20966338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YH</given-names></name><name><surname>Mo</surname><given-names>QG</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>LQ</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Axillary fine needle aspiration cytology is a sensitive and highly specific technique for the detection of axillary lymph node metastasis: a meta-analysis and systematic review</article-title><source>Cytopathology</source><year>2016</year><volume>27</volume><issue>1</issue><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/cyt.12224</pub-id><pub-id pub-id-type="pmid">25496004</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yu YH, Mo QG, Zhu X, Gao LQ, Liang C, Huang Z et al (2016) Axillary fine needle aspiration cytology is a sensitive and highly specific technique for the detection of axillary lymph node metastasis: a meta-analysis and systematic review. Cytopathology 27(1):59&#x02013;69<pub-id pub-id-type="pmid">25496004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Hukkinen</surname><given-names>K</given-names></name><name><surname>Kivisaari</surname><given-names>L</given-names></name><name><surname>Heikkil&#x000e4;</surname><given-names>PS</given-names></name><name><surname>Von Smitten</surname><given-names>K</given-names></name><name><surname>Leidenius</surname><given-names>M</given-names></name></person-group><article-title>Unsuccessful preoperative biopsies, fine needle aspiration cytology or core needle biopsy, lead to increased costs in the diagnostic workup in breast cancer</article-title><source>Acta Oncol</source><year>2008</year><volume>47</volume><issue>6</issue><fpage>1037</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1080/02841860802001442</pub-id><pub-id pub-id-type="pmid">18607862</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hukkinen K, Kivisaari L, Heikkil&#x000e4; PS, Von Smitten K, Leidenius M (2008) Unsuccessful preoperative biopsies, fine needle aspiration cytology or core needle biopsy, lead to increased costs in the diagnostic workup in breast cancer. Acta Oncol 47(6):1037&#x02013;1045<pub-id pub-id-type="pmid">18607862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>BSW</given-names></name><name><surname>Ng</surname><given-names>JKM</given-names></name><name><surname>Tsang</surname><given-names>JYS</given-names></name><name><surname>Tse</surname><given-names>GMK</given-names></name></person-group><article-title>Predictors of an informative or actionable cytological diagnosis on repeat breast aspiration after an insufficient aspirate: a multicentre retrospective review</article-title><source>J Clin Pathol</source><year>2024</year><pub-id pub-id-type="doi">10.1136/jcp-2023-209250</pub-id><pub-id pub-id-type="pmid">39667850</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Li J, Lai BSW, Ng JKM, Tsang JYS, Tse GMK (2024) Predictors of an informative or actionable cytological diagnosis on repeat breast aspiration after an insufficient aspirate: a multicentre retrospective review. J Clin Pathol. 10.1136/jcp-2023-209250<pub-id pub-id-type="pmid">39667850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>K</given-names></name><name><surname>Ogiya</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Morizono</surname><given-names>H</given-names></name><name><surname>Iijima</surname><given-names>K</given-names></name><name><surname>Miyagi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer</article-title><source>World J Surg Oncol</source><year>2010</year><volume>8</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1477-7819-8-6</pub-id><pub-id pub-id-type="pmid">20105298</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tada K, Ogiya A, Kimura K, Morizono H, Iijima K, Miyagi Y et al (2010) Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer. World J Surg Oncol 8:6<pub-id pub-id-type="pmid">20105298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Cserni</surname><given-names>G</given-names></name><name><surname>Ambr&#x000f3;zay</surname><given-names>&#x000c9;</given-names></name><name><surname>Ser&#x000e9;nyi</surname><given-names>P</given-names></name><name><surname>Bori</surname><given-names>R</given-names></name><name><surname>Sejben</surname><given-names>I</given-names></name><name><surname>Cs&#x000f6;rg&#x00151;</surname><given-names>E</given-names></name><etal/></person-group><article-title>Preoperative axillary nodal staging of invasive lobular breast cancer with ultrasound guided fine needle aspiration in patients with suspicious ultrasound findings versus aspiration in all patients&#x02013;a retrospective single institutional analysis</article-title><source>Eur J Surg Oncol</source><year>2022</year><volume>48</volume><issue>4</issue><fpage>742</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2021.11.130</pub-id><pub-id pub-id-type="pmid">34872778</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Cserni G, Ambr&#x000f3;zay &#x000c9;, Ser&#x000e9;nyi P, Bori R, Sejben I, Cs&#x000f6;rg&#x00151; E et al (2022) Preoperative axillary nodal staging of invasive lobular breast cancer with ultrasound guided fine needle aspiration in patients with suspicious ultrasound findings versus aspiration in all patients&#x02013;a retrospective single institutional analysis. Eur J Surg Oncol 48(4):742&#x02013;747<pub-id pub-id-type="pmid">34872778</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>